SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

13 Aug 2025 Evaluate
The sales is pegged at Rs. 1450.74 millions for the June 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 1606.26 millions during the year-ago period.The Company's Net profit for the June 2025 quarter have declined marginally to Rs. 347.90  millions as against Rs. 446.44 millions reported during the corresponding quarter ended.The company reported a degrowth in operating Profit to 543.75 millions from 647.66 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 1450.74 1606.26 -9.68 1450.74 1606.26 -9.68 6964.85 5703.40 22.12
Other Income 26.74 22.24 20.23 26.74 22.24 20.23 98.15 106.35 -7.71
PBIDT 543.75 647.66 -16.04 543.75 647.66 -16.04 2706.11 1836.10 47.38
Interest 5.12 3.35 52.84 5.12 3.35 52.84 16.86 21.10 -20.09
PBDT 538.63 644.31 -16.40 538.63 644.31 -16.40 2689.25 1815.00 48.17
Depreciation 64.51 46.56 38.55 64.51 46.56 38.55 204.44 158.11 29.30
PBT 474.12 597.75 -20.68 474.12 597.75 -20.68 2484.81 1656.89 49.97
TAX 126.22 151.31 -16.58 126.22 151.31 -16.58 605.23 465.76 29.94
Deferred Tax 20.87 4.64 349.78 20.87 4.64 349.78 38.66 94.76 -59.20
PAT 347.90 446.44 -22.07 347.90 446.44 -22.07 1879.58 1191.13 57.80
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 37.48 40.32 -7.04 37.48 40.32 -7.04 38.85 32.19 20.69

Supriya Lifescience Share Price

637.05 -0.90 (-0.14%)
13-Apr-2026 12:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.50
Dr. Reddys Lab 1228.75
Cipla 1212.55
Zydus Lifesciences 923.65
Lupin 2320.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×